-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BI-1206 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BI-1206 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BI-1206 in Solid Tumor Drug Details: BI-1206 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Avapritinib in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Avapritinib in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Avapritinib in Breast Cancer Drug Details: Avapritinib (Ayvakit, Ayvakyt) is an anti-neoplastic...
-
Company Insights
Innovation and Patenting activity of Blueprint Medicines Corp Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Blueprint Medicines Corp Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMPT-314 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMPT-314 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMPT-314 in Follicular Lymphoma Drug Details: IMPT-314 is under investigation for the...
-
Product Insights
NewHypersecretory Conditions – Drugs In Development, 2024
Empower your strategies with our Hypersecretory Conditions – Drugs In Development, 2024 report and make more profitable business decisions. Hypersecretory Condition is a group of disorders characterized by hypersecretion of gastric acid also known as hypergastrinemia. This condition can result in peptic ulcers, GERD, gastrointestinal hemorrhage causing a predominant mortality and morbidity. Underlying diseases, helicobacter pylori infection, gastric outlet obstruction, chronic renal failure and idiopathic causes results to hypersecretion of gastric juice. Diagnosed by the gastrin levels and gastric acid secretion...
-
Product Insights
NewSystemic Mastocytosis – Drugs In Development, 2024
Empower your strategies with our Systemic Mastocytosis – Drugs In Development, 2024 report and make more profitable business decisions. Systemic mastocytosis is a disorder where mast cells are abnormally increased in multiple organs including the bone marrow. Symptoms include shortness of breath, low blood pressure, hives and swelling, itching, diarrhea, headache, flushing, and musculoskeletal pain. Treatment includes antihistamines and more aggressive forms of medication, including interferon or chemotherapeutic agents. The Systemic Mastocytosis drugs in development market research report provide comprehensive information...
-
Product Insights
NewMast Cell Leukemia – Drugs In Development, 2024
Empower your strategies with our Mast Cell Leukemia – Drugs In Development, 2024 report and make more profitable business decisions. Mast cell leukemia (MCL) is a rare and aggressive type of blood cell cancer. It is a subtype of systemic mastocytosis (SM) and caused by the abnormal growth of cells from myeloid progenitor cells. Symptoms include lethargy and weakness, fainting, flushing, fever, tachycardia, losing more than 10 percent of body weight, diarrhea, nausea, and vomiting. MCL diagnosis requires fulfillment of diagnostic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Avapritinib in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Avapritinib in Solid Tumor Drug Details: Avapritinib (Ayvakit, Ayvakyt) is an anti-neoplastic agent. It is...
-
Product Insights
NewGastrointestinal Stromal Tumor (GIST) – Drugs In Development, 2024
Empower your strategies with our Gastrointestinal Stromal Tumor (GIST) – Drugs In Development, 2024 report and make more profitable business decisions. Gastrointestinal stromal tumors (GISTs) are tumors that occur in the gastrointestinal tract. GISTs belong to a group of cancers called soft tissue sarcomas. GISTs can be benign or malignant. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can be felt with the hand, nausea and vomiting, vomiting blood or having blood...